Median progression-free survival was 3.7 months, with 44.4% of patients being progression free at 6 months and 32.3% at 12 ...

The National Cancer Center Research Institute in Tokyo reports that a newly isolated gut bacterium, designated ...

AnaptysBio’s lead drug rosnilimab showed promise in RA, but lack of a Phase 3 plan and limited pipeline raise concerns. Find ...

Explore how the ratio of pd-1+ treg to ctl and the presence of tertiary lymphoid structures can influence treatment outcomes in advanced gastric cancer.

Objective: PD-1/PD-L1 inhibitors are novel immunotherapeutic agents that have been approved for first-line treatment in advanced non-small cell lung cancer (NSCLC). This study aims to evaluate the ...

Methods: Here, we describe the in vitro characterization, functional and preclinical evaluation of JS207, a novel BsAb targeting PD-1 and VEGFA with high antigen binding affinity. JS207 matched or ...

AMG 404 is a human IgG1 monoclonal antibody (mAb) with high affinity, potency and binding ability for PD-1, inhibiting receptor-ligand interaction. The fragment crystallisable (Fc) region was modified ...